A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

NCT01709084 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

426

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus-type 1 Infection

Interventions

DRUG: Rilpivirine
DRUG: Efavirenz
DRUG: Tenofovir disoproxil fumarate
DRUG: Emtricitabine

Sponsor

Janssen-Cilag International NV